CND Life Sciences Secures Growth Financing for Neurodiagnostics Platform
The funding will support the expansion of the Syn-One Test, a skin biopsy-based laboratory developed test for neurodegenerative diseases.
Category: Dementias & Alzheimer’s
Dementias & Alzheimer’s
Latest
Dementias & Alzheimer’s
Latest
First Commercial Alzheimer’s Tau Tangle Blood Test Launches
The eMTBR-Tau assay measures tau tangle pathology in blood, with potential applications in Alzheimer’s disease staging, clinical trials, and therapy monitoring.
Dementias & Alzheimer’s
Latest
Sysmex Europe Launches Automated Blood Testing Platform for Alzheimer’s Disease
The system uses routine blood draws to provide results in 17 minutes, offering an alternative to invasive diagnostic methods.
Researchers Develop Test to Detect Biomarkers for Specific Type of Dementia
Researchers at Mass General Brigham have developed a digital seed amplification assay that detects TDP-43 protein seeds in cerebrospinal fluid, enabling identification of FTLD-TDP, a specific frontotemporal lobar degeneration subtype.
Read More
Alzheimer’s Blood-Based Biomarker Testing Integrated into Clinical Workflows
Lucent Diagnostics and Tempus AI have partnered to integrate blood-based Alzheimer’s biomarker testing into clinical workflows, aiming to expand access and improve detection accuracy for neurologists.
Read More
Roche Receives CE Mark for Alzheimer’s Disease Blood Test
Roche has received CE mark approval for its Elecsys pTau217 blood test, designed to aid in Alzheimer’s disease diagnosis by detecting amyloid pathology in patients with cognitive decline.
Read More
NeuroVision Acquires Durin Life Sciences for Neurodegenerative Disease Diagnostics
NeuroVision Imaging has acquired Durin Life Sciences, combining blood-based biomarker tests with retinal imaging and telehealth to advance early detection of Alzheimer’s and Parkinson’s diseases.
Read More
Fujirebio Receives CE Mark for New Alzheimer’s Disease Plasma Assay
Fujirebio Europe has received CE marking for its automated Lumipulse G pTau 217 Plasma assay, designed to help identify amyloid pathology in patients with cognitive decline, according to the company.
Read More
Blood Test Predicts Alzheimer’s Progression in Cognitively Healthy Older Adults
Research shows the pTau217 biomarker can identify risk for cognitive decline and amyloid buildup before changes appear on brain scans.
Read More
New Partnership Aims to Improve Early Alzheimer’s Disease Detection
Circular Genomics and Vitazi.ai have formed a partnership to combine AI-driven retinal imaging and blood-based RNA biomarkers for early Alzheimer’s disease detection, aiming to address gaps in early-stage patient identification.
Read More
Clinical Trial to Evaluate Finger-Prick Blood Test for Alzheimer’s Diagnosis
The study will analyze three key proteins to determine if blood-based biomarkers can provide an earlier and more accessible diagnostic method.
Read More
Gut-Derived Blood Markers May Detect Early Cognitive Decline Before Symptoms
Researchers at the University of East Anglia report that gut-derived blood markers may help detect early cognitive decline before symptoms, according to findings published in Gut Microbes.
Read More
Concussion Blood Test Advances Toward FDA Submission With Point-of-Care Collaboration
BRAINBox Solutions reports near-completion of its HeadSMART II trial for a concussion blood test, supporting an upcoming FDA submission, and advances in a point-of-care biomarker collaboration with Prolight Diagnostics.
Read More
C2N Diagnostics’ eMTBR-tau243 Plasma Assay Used in Alzheimer’s Phase 3 Trial Dataset
The biomarker showed independent associations with cognitive and functional decline, offering complementary information alongside p-tau217 in early symptomatic Alzheimer’s disease.
Read More
New Ultra-Sensitive Assays Aim to Improve Early Detection of Alzheimer’s and Parkinson’s Disease
Three new immunoassays targeting key neurodegeneration biomarkers require just 1 µL of plasma and run on standard laboratory instruments.
Read More
Researchers Develop First DNA Aptamers That Bind Alzheimer’s Blood Biomarker Neurofilament Light Chain
The newly identified aptamers match antibody-level binding strength and could support the development of lower-cost, point-of-care blood tests for neurodegeneration.
Read More
ADDF Launches Third Phase of Diagnostics Accelerator with $50 Million to Advance Alzheimer’s Blood Tests and AI Biomarkers
The new funding brings the initiative’s total to $150 million and will focus on tau pathology, multi-marker panels, and AI-driven diagnostics.
Read More
Siemens Healthineers Expands Brain Health Research Portfolio with New Blood-Based Tau Assays
Siemens Healthineers has introduced two new blood-based tau assays for research use on the Atellica platform, expanding its brain health portfolio with tests aimed at advancing neurodegenerative disease research.
Read More